ClinicalTrials.gg
Active, not recruitingNCT07431086Updated Jun 17, 2026

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

A Phase 2 interventional study of Olatorepatide and Placebo in Overweight or Obesity, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity.

The study will test how safe and effective the study drug works compared to placebo in people who are overweight or obese but do not have diabetes.

The study is looking at:

  • What side effects the study drug might cause
  • How much the study drug is in the blood at different times
  • How well the study drug works
  • If the body makes antibodies to the study drug as this may cause the study drug to not work as well
02

Conditions studied

  • Overweight or Obesity

Browse trials for

Keywords

  • Body weight
  • Waist circumference
  • Glucagon-Like Peptide-1 (GLP-1) receptor agonist
  • Control appetite
  • Glucose-dependent Insulinotropic Polypeptide (GIP)
03

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 120 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. ≥27.0 kg/m\^2 to \<45.0 kg/m\^2 at screening
  2. Demonstrates ability and willingness to comply with the study protocol, including attending all scheduled visits, adhering to the prescribed treatment regimen, and completing all required assessment

Key Exclusion Criteria:

  1. History of Type 1 or Type 2 diabetes
  2. Change in body weight >5 kg within approximately 3 months before screening as described in the protocol
  3. Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions, prior to randomization or planned during the study period
  4. History of any of the following conditions: acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones or has a history of an active or untreated or are in remission from a malignancy for less than 5 years as described in the protocol

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    General Cohort

    Drug: Olatorepatide · Drug: Placebo

  • Experimental
    Subgroup Cohort

    Drug: Olatorepatide · Drug: Placebo

Interventions

  • Administered per the protocol

    Also known as: HS-20094

  • DrugPlacebo

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 30 weeks

  2. Severity of TEAEs

    Time frame: Up to approximately 30 weeks

  3. Maximum plasma Concentration (Cmax)

    Time frame: At week 15 and week 24

  4. Area Under the Concentration time curve from time 0 to 168 hours (AUC0-168h)

    Time frame: At week 15 and week 24

Secondary outcomes

  1. Percent change in body weight

    Time frame: From baseline to week 25

  2. Change in mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP)

    Time frame: From baseline to weeks 7, 15 and 24

  3. Change in in-clinic SBP

    Time frame: From baseline to weeks 7, 15 and 24

  4. Lowest concentration in a dosing interval (Ctrough)

    Time frame: Up to approximately 30 weeks

  5. Time to Cmax (Tmax)

    Time frame: Up to approximately 30 weeks

  6. Apparent Volume of distribution (Vd/F)

    Time frame: Up to approximately 30 weeks

  7. Apparent clearance (CL/F)

    Time frame: Up to approximately 30 weeks

  8. Apparent terminal half-life (t½)

    Time frame: Up to approximately 30 weeks

  9. Olatorepatide concentrations

    Time frame: Up to approximately 30 weeks

  10. Occurrence of Anti-Drug Antibody (ADA) to olatorepatide

    Time frame: Up to approximately 30 weeks

  11. Magnitude of ADA to olatorepatide

    Time frame: Up to approximately 30 weeks

  12. Corrected QT interval using the Fridericia formula (QTcF)

    Time frame: Pre-dose to up to 48 hours post-dose

07

Study locations

3 sites
  • Diablo Clinical Research - Flourish Research
    Walnut Creek, California 94598, United States
  • Clinical Site Partners, LLC DBA Flourish Research
    Winter Park, Florida 32789, United States
  • Flourish Research - San Antonio Medical Trials
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 7 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 7 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Feb 24, 2026
StartActual
Mar 16, 2026
Primary completionEst.
Nov 13, 2026
CompletionEst.
Dec 18, 2026
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07431086
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Mar 16, 2026
Primary completion
Nov 13, 2026 (estimated)
Completion
Dec 18, 2026 (estimated)
Last update
Jun 17, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olatorepatide

Start the discussion